Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 424-433

  Sánchez De La Rosa, Rainel ^a   Sabater, Eliazar ^b   Casado, Miguel Angel ^b   Arroyo, Rafael ^c  

^a TEVA PHARMACEUTICALS   (Israel)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Disease modifying drugs (DMD); Glatiramer acetate; Interferons; Markov chain; Relapsing remitting multiple sclerosis (RRMS)

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRODUCTIVITY; SPAIN;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INTERFERONS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; SPAIN;

EID: 84859172556     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.654868     Document Type: Article

References (57)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52
2. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989;11:133-46
4. Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragó n, Spain. J Neurol Sci 2003;216:89-93
5. Aladro Y, Alemany MJ, Pé rez-Vieitez MC, et al. Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005;24:70-5
6. Ares B, Prieto JM, Lema M, et al. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler 2007;13:262-4
7. Garcý́a Merino A, Ferná ndez O, Montalbá n X, et al. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: Escalating therapy]. Neurologia 2010;25:378-90
8. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ: HEPAC: Health Econ Prev Care 2006;7:S65-S74
9. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77: 918-26
10. Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. Cuá nto cuesta un brote de esclerosis mú ltiple en Cataluñ a. Neurologia 2006;21:341-7
11. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on long-Term clinical data. J Manag Care Pharm 2007;13: 245-61.
12. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008;14:679-90
13. Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
14. Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: Modelling the clinical and economic implications. Pharmacoeconomics 2009;27:39-53
15. Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther 2010;32:717-28
16. Janković SM, Kostić M, Radosavljević M, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition. Vojnosanit Pregl 2009;66:556-62
17. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of diseasemodifying therapy for multiple sclerosis: A population-based study. Neurology 2011 26;77:355-63
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52
19. Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-68
20. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: Results from an epidemiological survey in northeast Scotland. J Neurol Neurosurg Psychiatry 1987;50:523-31
21. Instituto Nacional de Estadý́stica. Revisió n del Padró n municipal 2010. Datos a nivel nacional. INE 2011. http://www.ine.es/jaxi/tabla.do. Accessed at 7/2/2011
22. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: A cross-sectional observational study in Germany. Stockholm School of Economics Working Paper Series in Economics and Finance. Final Version - August 12, 2000
23. Ford CC, Johnson KP, Lisak RP, et al. Copaxone Study Group. A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20
24. López Bastida J, Oliva J, Antoñ anzas F, et al. Propuesta de guý́a para la evaluació n econó mica aplicada a las tecnologý́as sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluació n del Servicio Canario de la Salud; 2008. Informes de Evaluació n de Tecnologý́as Sanitarias: SESCS N 2006/22. http://aunets.isciii.es/ficherosproductos/132/MemoriaFinal.pdf. Accessed at 18/10/2010
25. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61
26. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
27. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-12
28. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34
29. Instituto Nacional de Estadý́stica. Defunciones segú n la Causa de Muerte 2008. Resultados nacionales. INE 2010. http://www.ine.es/ jaxi/tabla.do?path/t15/p417/a2008/l0/&file01001.px&typepcaxis&L0. Accessed at 7/2/2011
30. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
31. Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004;10:139-44
32. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
33. PRISMS (Prevention of Relapses and Disability by Interferon -1a subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: Long-Term efficacy of interferon- -1a in relapsing MS. Neurology 2001;56:1628-36
34. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
35. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85
36. Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 2009;277:S29-32
37. EuroQol - A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
38. Badia X, Roset M, Monserrat S, et al. La versió n españ ola del EuroQol: Descripció n y aplicaciones. Med Clin (Barc) 1999;112(1Suppl):79-85
39. Badý́a X, Montserrat S, Roset M, et al. Feasibility, validity and test-retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off. Qual Life Res 1999;8:303-10
40. Instituto Nacional de Estadý́stica. Índice de precios al consumo 2009. Base 2006. Resultados nacionales INE 2010. http://www.ine.es/jaxi/menu.do? typepcaxis&path/t25/ p138&fileinebase&L0. Accessed at 7/2/2011
41. European Medicines Agency (EMEA). European public assessment report (EPAR) for Avonex. Summary of product Characteristics (last updated 22/09/2011). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000102/WC500029425.pdf. Accessed 30/12/2011
42. European Medicines Agency (EMEA). European public assessment report (EPAR) for Betaferon. Summary of product Characteristics (last updated 18/10/2011). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000081/WC500053225.pdf. Accessed 30/12/2011
43. European Medicines Agency (EMEA). European public assessment report (EPAR) for Extavia. Summary of product Characteristics (last updated 22/06/2011). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000933/WC500034701.pdf. Accessed 30/12/2011
44. European Medicines Agency (EMEA). European public assessment report (EPAR) for Rebif. Summary of product Characteristics (last updated 22/06/2011). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000933/WC500034701.pdf. Accessed 30/12/2011
45. Ministerio de Sanidad y Política Social. Agencia Españ ola de medicamentos y productos sanitarios. ficha té cnica Copaxone. Summary of product Characteristics (last updated September 2009). Available at: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf& codigo=65983&formato=pdf&formulario=FICHAS&file=ficha.pdf. Accessed 30/12/2011
46. Consejo General de Colegios de Farmacé uticos. Catá logo de especialidades farmacé uticas. Consejo Plus 2009. Madrid: Consejo General de Colegios de Farmacé uticos; 2007. http://www.portalfarma.com. Accessed at 7/2/2011
47. Instituto Nacional de Estadística. Condiciones de trabajo y relaciones laborales Salario mínimo interprofesional. Serie 1990-2010. INE 2011. http://www.ine.es/jaxi/tabla.do?typepcaxis&path/t22/a063/a1998/l0/ &file m30026.px. Accessed at 7/2/2011
48. Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006;27:143-51
49. Sacristán JA, Oliva J, Del Llano J, et al. Qué es una tecnologý́a sanitaria eficiente en Españ a? Gac San 2002;16:334-43
50. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 2004;10(Suppl):S12-19. http://www.amcp.org/data/jmcp/ June04Supplement1.pdf. Accessed March 5, 2007
51. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
52. Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
53. Rubio-Terré s C, Arý́stegui Ruiz I, Medina Redondo F, et al. Aná lisis coste-utilidad del tratamiento de la esclerosis multiple remitente-recidivante con acetate de glatiramero o interferó n beta en Españ a. Farm Hosp 2003;27:159-65
54. Garrison Jr. LP,, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: The ISPOR Real-World Data Task Force report. Value Health 2007;10:326-35
55. Goeree R, Burke N, O'Reilly D, et al. Transferability of economic evaluations: Approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin 2007;23:671-82
56. Panitch H, Goodin D, Francis G, et al; EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained at 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239: 67-74
57. Mikol DD, Barkhof F, Chang P, et al. REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14 Journal of Medical Economics Volume 15, Number 3 June 2012 ! 2012 Informa UK Ltd www.informahealthcare.com/jme Cost-effectiveness analysis of first line treatments in RRMS Sá nchez-de la Rosa et al. 433